Genomics, Inc. (NASDAQ:TXG – Get Free Report) has received a consensus recommendation of “Hold” from the seventeen analysts ...

Analysts at Leerink Partnrs decreased their Q1 2025 earnings estimates for shares of 10x Genomics in a research note issued to investors on Thursday, February 13th. Leerink Partnrs analyst P. Souda ...

10x Genomics maintains strong fundamentals despite current headwinds. InvestingPro analysis indicates the stock is currently slightly undervalued based on its Fair Value model, offering potential ...

10x Genomics (NASDAQ:TXG), a leading player in the single-cell and spatial genomics technologies sector, finds itself at a critical juncture as it navigates through a challenging market environment.

The NIH projected the cut will save it $4 billion during the current federal fiscal year, which ends September 30. That’s ...